Vertex operates at the forefront of scientific innovation and has successfully developed and commercialized multiple breakthrough medicines for Cystic Fibrosis (CF) as well as Casgevy, a gene therapy for sickle cell disease and beta-thalassemia. Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases including programs in Pain, APOL-1 mediated kidney disease (AMKD), and cell therapies for Type 1 diabetes, among others. Povetacicept is a highly potent and effective dual antagonist of BAFF and APRIL pathways with potential best-in-class efficacy in patients with IgA nephropathy (IgAN) and primary membranous nephropathy (pMN). IgAN is a serious, progressive, autoimmune disease of the kidney that can lead to end-stage-renal disease. There are no approved therapies that target the underlying cause of IgAN. IgAN is the most common cause of primary (idiopathic) glomerulonephritis worldwide. Due to its mechanism of action as a dual BAFF/APRIL antagonist, povetacicept holds the potential to benefit patients for multiple serious diseases including other autoimmune kidney diseases and autoimmune cytopenias. Vertex is expanding its Global Value and Access Strategy (GVAS) team to support the launch of this exciting product. Market Access is a key commercial function that ensures transformative Vertex therapies are appropriately funded and ultimately make it into the hands of the patients around the world. GVAS works cross-functionally and across regions to ensure the payer view is represented in commercial and development plans across the lifecycle. We are driven by a desire to deliver groundbreaking pricing & reimbursement solutions to allow our medicines to reach patients faster than ever before.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior
Industry
Chemical Manufacturing
Education Level
Bachelor's degree
Number of Employees
1,001-5,000 employees